Our client, the Indiana Biosciences Research Institute (IBRI) in Indianapolis is bringing together several big industry names for a major study on how type 2 diabetes varies in different patients. Chief Executive Officer David Broecker says the “first-of-its-kind” partnership involves Eli Lilly and Co., Roche Diagnostics Corp., the Regenstrief Institute and Indiana University School of Medicine. He says the collaboration will give researchers access to information on more than 800,000 people with type 2 diabetes throughout Indiana.
About the Indiana Biosciences Research Institute
The Indiana Biosciences Research Institute (IBRI) was founded on the principle of “Discovery with Purpose.” The Institute’s goal is to deliver research that has a meaningful impact on the lives of people, beginning with those affected by diabetes, metabolic disease, and poor nutrition.
From its inception in 2013, the IBRI has steadily developed partnerships, acquired funding and built the systems to create an environment where research can be done and then translated into innovation and new technologies. With the help of its Scientific Advisory Board, composed of top scientists from the IBRI’s industry partners–Lilly, Roche Diagnostics, Cook Medical, and Dow AgroSciences–the IBRI has identified key research areas including metabolic discovery and translation, applied data sciences, and single cell bioanalytics.